Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more.
The follow-on public offering (FOPO) category made up the made up most (34%) of the aggregate Q3 financing dollars (see Exhibit 1). During Q3, there were 39 FOPOs in all, of which 15 deals totaled $100m or more, and one topped a billion dollars. Vaxcyte (engineering high-fidelity vaccines to protect from bacterial diseases) netted
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?